Cowen analyst Ritu Baral reiterated an Outperform rating on uniQure BV (NASDAQ: QURE) Ph1/2 12 mo. MPS3b AMT-110 data was ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

uniQure (QURE) Ests and PT Cut After Dropping Glybera - JefferiesDecember 1, 2015 9:49 AM uniQure BV (QURE) Sell-Off 'Unfounded' - OppenheimerDecember 1, 2015 7:11 AM uniQure (QURE) Misses Q3 EPS by 3cNovember 30, 2015 7:34 AM uniQure Announces Financial Results for Third Quarter 2015 and Provides Update on Product Pipeline and Company DevelopmentsNovember 30, 2015 7:30 AM